GLUD1 and colorectal carcinoma: SIRT5 supports the anaplerotic entry of glutamine into the tricarboxylic-acid (TCA) cycle in malignant phenotypes of colorectal cancer (CRC) via activating glutamate dehydrogenase 1 (GLUD1) [28].